Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 6/20 | 0.42 |
| ▸ | GLS | O94925 | 4/20 | 0.42 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19471088 | 1.00 | IDH1 (0.42) | IDH1GLSSCD5NPC1LMNA | |
| SCHEMBL9733041 | 0.86 | GLS (0.42) | IDH1GLSSCD5NPC1LMNA | |
| SCHEMBL4731676 | 0.86 | GLS (0.42) | IDH1GLSSCD5NPC1LMNA | |
| SCHEMBL29053818 | 0.82 | LMNA (0.44) | IDH1GLSSCD5NPC1LMNA | |
| SCHEMBL29053815 | 0.82 | LMNA (0.44) | IDH1GLSSCD5NPC1LMNA | |
| SCHEMBL17870942 | 0.80 | GLS (0.46) | IDH1GLSSCD5NPC1LMNA | |
| SCHEMBL266818 | 0.80 | GLS (0.46) | IDH1GLSSCD5NPC1LMNA | |
| SCHEMBL8138150 | 0.80 | HDAC1 (0.44) | IDH1GLSSCD5NPC1LMNA | |
| SCHEMBL12333636 | 0.80 | GLS (0.46) | IDH1GLSSCD5NPC1LMNA | |
| SCHEMBL2065159 | 0.78 | GLS (0.43) | IDH1GLSSCD5NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11090307-B2 | Treating male senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-08-17 | — | — | US | disclosed |
| CN-107108492-B | Cell necrosis inhibitor | 北京生命科学研究所 | 2021-03-19 | — | — | CN | disclosed |
| US-20200182617-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-06-11 | — | — | US | disclosed |
| US-20200046714-A1 | Treating Male Senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-02-13 | — | — | US | disclosed |
| US-10555920-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-02-11 | — | — | US | disclosed |
| US-10555920-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-02-11 | — | — | US | disclosed |
| US-20190038578-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2019-02-07 | — | — | US | disclosed |
| US-20190038578-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2019-02-07 | — | — | US | disclosed |
| US-10092529-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-10-09 | — | — | US | disclosed |
| US-20170304237-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-10-26 | — | — | US | disclosed |
| US-20170304237-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-10-26 | — | — | US | disclosed |
| US-20170304237-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-10-26 | — | — | US | disclosed |
| EP-3224245-A1 | NECROSIS INHIBITORS | National Institute Of Biological Sciences, Beijing (CN) | 2017-10-04 | — | — | EP | disclosed |
| WO-2016101887-A1 | NECROSIS INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016101887-A1 | NECROSIS INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304237-A1 | Necrosis Inhibitors | RIPK3, RIPK1, RIPK4 | IDH1 704/4885GLS 1766/4885SCD5 998/4885 |
| US-11090307-B2 | Treating male senescence | RIPK3, RIPK1, MLKL | IDH1 2426/4885GLS 1689/4885SCD5 1189/4885 |
| US-20200046714-A1 | Treating Male Senescence | RIPK3, RIPK1, MLKL | IDH1 2426/4885GLS 1689/4885SCD5 1189/4885 |
| US-20190038578-A1 | Necrosis Inhibitors | RIPK3, RIPK1, RIPK4 | IDH1 1249/4885GLS 2215/4885SCD5 1086/4885 |
| US-10092529-B2 | Necrosis inhibitors | RIPK3, RIPK1, RIPK4 | IDH1 704/4885GLS 1766/4885SCD5 998/4885 |
| US-10555920-B2 | Necrosis inhibitors | RIPK3, RIPK1, RIPK4 | IDH1 1249/4885GLS 2215/4885SCD5 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.